Role of iNO in the modulation of pulmonary vascular resistance

Journal of Perinatology

Volumn 28, Issue , 2008, Pages S84-S92

  Bin Nun, A ^a   Schreiber, M D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; GUANYLATE CYCLASE ACTIVATOR; ILOPROST; LUNG SURFACTANT; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN D2; PROSTAGLANDIN E1; RECOMBINANT SUPEROXIDE DISMUTASE; RHO KINASE INHIBITOR; SILDENAFIL; SITAXSENTAN; SUPEROXIDE DISMUTASE; TOLAZOLINE; UNCLASSIFIED DRUG;

BLEEDING; BLEEDING TIME; BRONCHOSPASM; CLINICAL TRIAL; CONFERENCE PAPER; CONGENITAL DIAPHRAGM HERNIA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECHOCARDIOGRAPHY; EXTRACORPOREAL OXYGENATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; HYPOXEMIA; LOW DRUG DOSE; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; MECONIUM ASPIRATION; METHEMOGLOBINEMIA; NONHUMAN; OXYGEN SATURATION; PERSISTENT PULMONARY HYPERTENSION; PROGNOSIS; PULMONARY HYPERTENSION; REPERFUSION INJURY; RESPIRATORY FAILURE; SIDE EFFECT; SYSTEMIC DISEASE; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; HUMANS; INFANT, NEWBORN; NITRIC OXIDE; PERSISTENT FETAL CIRCULATION SYNDROME; VASCULAR RESISTANCE;

EID: 57649097673     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2008.161     Document Type: Review

References (48)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789): 373–376.
2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84(24): 9265–9269.
3. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327(6122): 524–526.
4. Murad F. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA 1996; 276(14): 1189–1192.
5. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353(25): 2683–2695.
6. Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 2003; 348(15): 1483–1485.
7. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83(6): 2038–2047.
8. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338(8776): 1173–1174.
9. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340(8823): 818–819.
10. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340(8823): 819–820.
11. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336(9): 597–604.
12. Roberts JD, Fineman JR, Morin III FC, Shaul PW, Rimar S, Schreiber MD et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336(9): 605–610.
13. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342(7): 469–474.
14. Martin RJ, Walsh MC. Inhaled nitric oxide for preterm infantsFwho benefits? N Engl J Med 2005; 353(1): 82–84.
15. Roberts JD, Chiche JD, Weimann J, Steudel W, Zapol WM, Bloch KD. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups. Circ Res 2000; 87(2): 140–145.
16. Barbotin-Larrieu F, Mazmanian M, Baudet B, Detruit H, Chapelier A, Libert JM et al. Prevention of ischemia–reperfusion lung injury by inhaled nitric oxide in neonatal piglets. J Appl Physiol 1996; 80(3): 782–788.
17. Shaul PW, Yuhanna IS, German Z, Chen Z, Steinhorn RH, Morin III FC. Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol 1997; 272(5 Part 1): L1005–L1012.
18. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006; (4): CD000399.
19. Clark PL, Ekekezie II, Kaftan HA, Castor CA, Truog WE. Safety and efficacy of nitric oxide in chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2002; 86(1): F41–F45.
20. Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, Ballard RA. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 1999; 103(3): 610–618.
21. Konduri GG, Vohr B, Robertson C, Sokol GM, Solimano A, Singer J et al. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. J Pediatr 2007; 150(3): 235–240, 240 e1.
22. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose–response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998; 101(3 Part 1): 325–334.
23. Guthrie SO, Walsh WF, Auten K, Clark RH. Initial dosing of inhaled nitric oxide in infants with hypoxic respiratory failure. J Perinatol 2004; 24(5): 290–294.
24. Loh E, Stamler JS, Hare JM, Loscalzo J, Colucci WS. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90(6): 2780–2785.
25. Semigran MJ, Cockrill BA, Kacmarek R, Thompson BT, Zapol WM, Dec GW et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994; 24(4): 982–988.
26. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R et al. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 1999; 104(2 Part 1): 231–236.
27. Oishi P, Grobe A, Benavidez E, Ovadia B, Harmon C, Ross GA et al. Inhaled nitric oxide induced NOS inhibition and rebound pulmonary hypertension: a role for superoxide and peroxynitrite in the intact lamb. Am J Physiol Lung Cell Mol Physiol 2006; 290(2): L359–L366.
28. Kirmse M, Hess D, Fujino Y, Kacmarek RM, Hurford WE. Delivery of inhaled nitric oxide using the Ohmeda INOvent Delivery System. Chest 1998; 113(6): 1650–1657.
29. Hogman M, Frostell C, Arnberg H, Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet 1993; 341(8861): 1664–1665.
30. Samama CM, Diaby M, Fellahi JL, Mdhafar A, Eyraud D, Arock M et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1995; 83(1): 56–65.
31. Ballard PL, Merrill JD, Truog WE, Godinez RI, Godinez MH, McDevitt TM et al. Surfactant function and composition in premature infants treated with inhaled nitric oxide. Pediatrics 2007; 120(2): 346–353.
32. Truog WE, Ballard PL, Norberg M, Golombek S, Savani RC, Merrill JD et al. Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. Pediatrics 2007; 119(4): 670–678.
33. Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005; 353(1): 23–32.
34. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 1997; 99(6): 838–845.
35. Kinsella JP, Parker TA, Ivy DD, Abman SH. Noninvasive delivery of inhaled nitric oxide therapy for late pulmonary hypertension in newborn infants with congenital diaphragmatic hernia. J Pediatr 2003; 142(4): 397–401.
36. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thebaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 2005; 172(6): 750–756.
37. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91(1): 307–310.
38. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20): 2148–2157.
39. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002; 165(8): 1098–1102.
40. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001; 29(5): 1000–1005.
41. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117(4): 1077–1083.
42. Deruelle P, Grover TR, Abman SH. Pulmonary vascular effects of nitric oxide–cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 2005; 289(5): L798–L806.
43. Ivy DD, Doran AK, Smith KJ, Mallory GB, Beghetti M, Barst RJ et al. Short- and longterm effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51(2): 161–169.
44. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002; 141(6): 830–832.
45. Ivy DD, Parker TA, Ziegler JW, Galan HL, Kinsella JP, Tuder RM et al. Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Invest 1997; 99(6): 1179–1186.
46. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2006; 3: CD004434.
47. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005; 171(5): 494–499.
48. Lakshminrusimha S, Russell JA, Wedgwood S, Gugino SF, Kazzaz JA, Davis JM et al. Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am J Respir Crit Care Med 2006; 174(12): 1370–1377.